IRIS
RUMI, ELISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.973
AS - Asia 3.926
EU - Europa 3.241
SA - Sud America 618
AF - Africa 84
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 12
Totale 12.867
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.840
CN - Cina 2.004
SG - Singapore 904
IE - Irlanda 867
HK - Hong Kong 574
BR - Brasile 523
RU - Federazione Russa 435
FI - Finlandia 390
DE - Germania 368
UA - Ucraina 282
IT - Italia 260
VN - Vietnam 187
SE - Svezia 152
GB - Regno Unito 143
FR - Francia 122
CA - Canada 73
IN - India 50
AT - Austria 42
AR - Argentina 41
MX - Messico 41
PL - Polonia 36
NL - Olanda 32
TR - Turchia 28
RO - Romania 27
ZA - Sudafrica 27
BD - Bangladesh 24
JP - Giappone 24
ES - Italia 18
CO - Colombia 16
IQ - Iraq 15
BE - Belgio 14
ID - Indonesia 14
EG - Egitto 12
JO - Giordania 12
AU - Australia 11
LT - Lituania 11
MA - Marocco 10
PK - Pakistan 10
AE - Emirati Arabi Uniti 9
PY - Paraguay 9
EC - Ecuador 8
KE - Kenya 8
SA - Arabia Saudita 8
VE - Venezuela 8
EU - Europa 7
MU - Mauritius 7
MY - Malesia 7
UZ - Uzbekistan 7
CH - Svizzera 6
CZ - Repubblica Ceca 6
AZ - Azerbaigian 5
IL - Israele 5
KR - Corea 5
LA - Repubblica Popolare Democratica del Laos 5
NP - Nepal 5
AL - Albania 4
CL - Cile 4
JM - Giamaica 4
KZ - Kazakistan 4
TN - Tunisia 4
UY - Uruguay 4
GR - Grecia 3
HN - Honduras 3
LB - Libano 3
LK - Sri Lanka 3
LV - Lettonia 3
NG - Nigeria 3
PE - Perù 3
PT - Portogallo 3
RS - Serbia 3
XK - ???statistics.table.value.countryCode.XK??? 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
BG - Bulgaria 2
BO - Bolivia 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GA - Gabon 2
GD - Grenada 2
GE - Georgia 2
HU - Ungheria 2
KG - Kirghizistan 2
MD - Moldavia 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
PA - Panama 2
PH - Filippine 2
SK - Slovacchia (Repubblica Slovacca) 2
TM - Turkmenistan 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BS - Bahamas 1
BW - Botswana 1
CM - Camerun 1
DK - Danimarca 1
ET - Etiopia 1
IM - Isola di Man 1
IS - Islanda 1
Totale 12.856
Salva come PNG Salva come JPEG
Città #
Dublin 866
Chandler 643
Hong Kong 573
Dallas 522
Ashburn 435
Jacksonville 425
Nanjing 394
Singapore 380
Beijing 352
Boardman 260
Princeton 167
Nanchang 163
Lawrence 158
Los Angeles 158
New York 138
Helsinki 137
Wilmington 121
Shenyang 118
Changsha 114
Hebei 110
Medford 101
Munich 97
Jiaxing 91
Ann Arbor 79
Shanghai 75
Tianjin 75
Ho Chi Minh City 74
Buffalo 73
Lauterbourg 70
Moscow 69
Redondo Beach 62
Hangzhou 61
São Paulo 46
Pavia 39
Milan 38
Nuremberg 36
Toronto 35
Seattle 34
Turku 34
Santa Clara 32
Woodbridge 29
Brooklyn 28
Norwalk 28
Warsaw 27
Hanoi 25
Denver 24
Falkenstein 23
Stockholm 22
Timisoara 22
The Dalles 21
Tokyo 21
Washington 21
Johannesburg 20
Montreal 20
Boston 19
Vienna 19
Rome 18
Chicago 17
San Francisco 17
London 16
Orem 16
Fairfield 15
Guangzhou 15
Rio de Janeiro 15
Brussels 14
Chennai 14
Jinan 14
Poplar 14
Houston 13
Mexico City 13
Atlanta 12
Florence 12
Frankfurt am Main 12
Verona 12
Zhengzhou 12
Amman 11
Ankara 11
Columbus 11
Manchester 11
Auburn Hills 10
Council Bluffs 10
Haiphong 10
Belo Horizonte 9
Charlotte 9
Curitiba 9
Falls Church 9
Ribeirão Preto 9
Buenos Aires 8
Magé 8
Ningbo 8
Pune 8
Bogotá 7
Campinas 7
Hải Dương 7
Manaus 7
Phoenix 7
Porto Alegre 7
Taizhou 7
Brasília 6
Cairo 6
Totale 8.307
Salva come PNG Salva come JPEG
Nome #
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 162
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 161
An insidious presentation of splenic marginal zone lymphoma 137
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 128
A novel germline JAK2 mutation in familial myeloproliferative neoplasms. 127
Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. 126
Blast phase of essential thrombocythemia: A single center study. 120
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. 120
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2 P95-mutated neoplasms 113
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations 112
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) 112
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 111
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms 111
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 110
High resolution genome-wide array-comparative genomic hybridization in splenic marginal zone B-cell lymphoma 109
Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients 106
CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis 105
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. 102
Tie2 expressing monocytes in the spleen of patients with primary myelofibrosis 102
JAK2 (V617F) mutation in healthy individuals 101
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea 101
Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin 100
Clinical significance of somatic mutation in unexplained blood cytopenia 100
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. 99
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms 95
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis 95
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms 95
Advances in understanding the pathogenesis of familial myeloproliferative neoplasms 92
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm. 90
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 90
Splenic marginal zone lymphoma: clinical clustering of immunoglobulin heavy chain repertoires 90
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. 89
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders 88
Clinical relevance of JAK2 (V617F) mutant allele burden 88
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients 88
Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms. 87
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 87
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression 87
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment 85
Peripheral intraneutrophil diplococci in a case of meningococcemia. 85
Allelic imbalance in CALR somatic mutagenesis 85
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 85
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 84
Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. 84
A journey through infectious risk associated with ruxolitinib. 84
Diagnosis and management of prefibrotic myelofibrosis. 83
Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosis 82
The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. 82
Clinical significance of genetic aberrations in secondary acute myeloid leukemia. 81
Cardiovascular events and intensity of treatment in polycythemia vera. 81
Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics. 81
Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms. 80
A prognostic model to predict survival in 867 WHO-defined essential thrombocythemia at diagnosis: a study by the IWG-MRT. 79
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders 79
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. 78
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. 78
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. 78
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients. 78
Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. 78
Facing erythrocytosis: Results of an international physician survey. 78
Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. 78
Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms 77
Role of the molecular staging and response in the management of follicular lymphoma patients 77
Familial chronic myeloproliferative disorders: the state of the art 77
Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. 77
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients 77
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19 77
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm 76
Arginase-1+ bone marrow myeloid cells are reduced in myeloproliferative neoplasms and correlate with clinical phenotype, fibrosis, and molecular driver 75
Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms. 75
Mutations and prognosis in primary myelofibrosis 75
Development and validation of an International Prognostic Score of thrombosis in WHO-Essential Thrombocythemia (IPSET-thrombosis). 75
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms 74
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. 74
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. 73
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. 73
Acute arterial and deep venous thromboembolism in COVID-19 patients: Risk factors and personalized therapy 73
Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. 72
Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms. 72
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis 72
Improving survival trends in primary myelofibrosis: an international study. 71
A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis 71
Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia 70
Platelet count predicts driver mutations’ co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis 70
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. 69
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. 69
Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. 68
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study 68
Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases 68
LIVER BIOPSY DURING SPLENECTOMY REVEALS THAT SPLENIC MARGINAL ZONE LYMPHOMA IS OFTEN AN HEPATO-SPLENIC DISEASE 67
Somatic mutations of calreticulin in myeloproliferative neoplasms 67
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. 67
Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms 67
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib 67
Type I but Not Type II Calreticulin Mutations Activate the IRE1α/XBP1 Pathway of the Unfolded Protein Response to Drive Myeloproliferative Neoplasms 66
Splenic marginal zone B-cell lymphoma in a HIV-positive patient: a case report 66
Mutational status of myeloproliferative neoplasms. 66
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. 66
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation 66
Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies. 65
Totale 8.677
Salva come PNG Salva come JPEG
Categoria #
all - tutte 63.925
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 63.925
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021404 0 0 0 0 0 62 10 106 53 89 66 18
2021/2022692 9 4 23 11 17 38 6 38 33 38 115 360
2022/20232.087 222 118 21 135 204 169 1 100 989 13 87 28
2023/20241.049 119 170 55 69 96 297 27 66 10 22 76 42
2024/20252.752 66 208 72 61 56 120 198 204 641 114 370 642
2025/20263.519 493 550 774 770 720 212 0 0 0 0 0 0
Totale 13.253